0001387131-21-003140 | 10-K | XBRL Viewer

Prescription Vitamins [Member]

$ 22,577,000

$ 19,343,000

$ 10,701,000

$ 12,251,000

$ 15,902,000

$ 23,719,000

$ 6,079,000

$ 3,947,000

$ 64,872,280

$ 49,646,937

$ 16,099,460

9,767,644

9,885,493

15,041,259

Imvexxy [Member]

27,139,387

16,252,045

1,058,201

BIJUVA [Member]

6,353,963

1,836,443

ANNOVERA [Member]

19,611,286

6,166,556

License [Member]

$ 2,000,000

$ 15,506,400

[1]	During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[2]	During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[3]	During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[4]	During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately $7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. Refer to discussion in Note 8-Debt.
[5]	During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[6]	During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[7]	During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Schedule of calculation of diluted net loss per share allocable to common stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	39,781,592	28,102,805	24,920,395
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,781,930	25,030,234	20,872,824
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,534,687	1,832,571	3,007,571
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,403,951
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,061,024	1,240,000	1,040,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)				1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 05, 2019 EUR (€)	Aug. 05, 2019 USD ($)	Jun. 06, 2019 EUR (€)	Jun. 06, 2019 EUR (€)	Dec. 31, 2020 USD ($) Number $ / shares	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) Number $ / shares	Dec. 31, 2019 USD ($) $ / shares	Dec. 31, 2018 USD ($)	Nov. 08, 2020 USD ($)
Product Information [Line Items]
Inventory charge						$ 5,700,000	$ 7,204,818	$ 0
Minimum cash balance requirement under credit agreement					$ 60,000,000		60,000,000
Cash FDIC insured amount					$ 250,000		$ 250,000
Number of issued patents domestic. \| Number					38		38
Number of issued patents foreign \| Number					39		39
Write off of patent and trademark cost					$ 500,000	$ 600,000	$ 1,131,776	$ 78,864
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.001		$ 0.001	$ 0.001
Amortization of intellectual property license fee							$ 3,024,391	$ 778,692
Advertising expense							$ 35,799,313	$ 9,045,571	$ 1,682,746
Council License Agreement [Member]
Product Information [Line Items]
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent							50.00%
Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent							20.00%
Maximum costs and expenses for post approval							$ 20,000,000
Council License Agreement Step 1
Product Information [Line Items]
Royalty (percent)							5.00%
Council License Agreement Step 2
Product Information [Line Items]
Royalty (percent)							10.00%
Council License Agreement Step 3
Product Information [Line Items]
Royalty (percent)							15.00%
License Agreement Theramex [Member]
Product Information [Line Items]
Cash upfront payment received	€ 14,000,000	$ 15,506,400
Minimum [Member] \| Council License Agreement Step 2
Product Information [Line Items]
Net sales amount per step-based royalty							$ 500,000
Minimum [Member] \| Council License Agreement Step 3
Product Information [Line Items]
Net sales amount per step-based royalty							$ 1,500,000
Minimum [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Sales milestone \| €			€ 25,000,000
Maximum [Member]
Product Information [Line Items]
Return period of unsalable prescription products							12 months
Maximum [Member] \| Council License Agreement Step 1
Product Information [Line Items]
Net sales amount per step-based royalty							$ 500,000
Maximum [Member] \| Council License Agreement Step 2
Product Information [Line Items]
Net sales amount per step-based royalty							$ 1,500,000
Maximum [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Regulatory milestone payments \| €			2,000,000	€ 2,000,000
Sales milestone payment \| €			27,500,000	€ 27,500,000
Sales milestone \| €			€ 100,000,000
Land and Building [Member] \| Minimum [Member]
Product Information [Line Items]
Useful life of assets							3 years
Land and Building [Member] \| Maximum [Member]
Product Information [Line Items]
Useful life of assets							7 years
Software and Software Development Costs [Member] \| Minimum [Member]
Product Information [Line Items]
Useful life of assets							5 years
Software and Software Development Costs [Member] \| Maximum [Member]
Product Information [Line Items]
Useful life of assets							7 years
Customer A [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							25.00%	36.00%
Customer B [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							19.00%	21.00%
Customer C [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							17.00%	16.00%
Customer D [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							11.00%	11.00%
Financing Agreement Amendment No. 6 [Member]
Product Information [Line Items]
Minimum cash balance requirement under credit agreement before adjustment										$ 60,000,000
Minimum cash balance requirement under credit agreement										$ 45,000,000
BIJUVA [Member]
Product Information [Line Items]
Inventory charge							$ 7,204,818
ANNOVERA [Member]
Product Information [Line Items]
Return period of unsalable prescription products							12 months
ANNOVERA [Member] \| Council License Agreement [Member]
Product Information [Line Items]
Milestone payment upon FDA Approval							$ 20,000,000
Milestone payments (payment after release of first commercial batch)							20,000,000
License rights acquired							20,000,000
Milestone payments upon specified levels of cumulative net sales							40,000,000
Specified level one of cumulative net sales for milestone payments							200,000,000
Specified level two of cumulative net sales for milestone payments							400,000,000
Specified level three of cumulative net sales for milestone payments							$ 1,000,000,000
Vitamins, IMVEXXY and BIJUVA [Member]
Product Information [Line Items]
Shelf life of prescription products							24 months
BIJUVA and ANNOVERA [Member]
Product Information [Line Items]
Shelf life of prescription products							18 months
BIJUVA and ANNOVERA [Member] \| Knight License Agreement [Member]
Product Information [Line Items]
Milestone payment received upon regulatory approval							$ 2,000,000
BIJUVA and ANNOVERA [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Quarterly royalty payments percentage				5.00%

Inventory consists of the following: (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished products	$ 3,350,580	$ 4,976,910
Work in process	219,918	1,182,059
Raw materials	4,422,589	5,701,747
TOTAL INVENTORY	$ 7,993,087	$ 11,860,716

Other current assets consist of the following: (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid sales and marketing costs	$ 4,308	$ 1,583,698
Debt financing fees on undrawn tranches (Note 8)		550,757
Prepaid insurance	2,568,269	1,812,135
Prepaid manufacturing	1,331,100	2,595,721
Other prepaid costs	3,639,720	4,787,482
TOTAL OTHER CURRENT ASSETS	$ 7,543,397	$ 11,329,793

Fixed assets, net consist of the following: (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	$ 3,683,671	$ 3,476,599
Accumulated depreciation	(1,741,447)	(968,824)
TOTAL FIXED ASSETS, NET	1,942,224	2,507,775
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	411,550	301,096
Equipment [Member]
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	1,704,931	1,619,646
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	1,406,858	1,406,858
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	80,211	80,211
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
TOTAL FIXED ASSETS	$ 80,121	$ 68,788

FIXED ASSETS, NET (Details Narrative) - USD ($)	12 Months Ended
FIXED ASSETS, NET (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 772,624	$ 415,193	$ 181,412

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	$ (748,627)	$ (478,983)
Intangible Assets, Gross (Excluding Goodwill)	5,996,350	5,737,194
Intangible assets, net	5,247,723	5,258,211
Multiple Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Trademarks	323,341	294,813
Indefinite-lived Intangible Assets (Excluding Goodwill)	323,341	294,813
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,044,552	3,463,082
Finite-Lived Intangible Assets, Accumulated Amortization	(748,627)	(478,983)
Finite-Lived Intangible Assets, Net	$ 3,295,925	$ 2,984,099
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years	13 years
Hormone Therapy Drug Candidate Patents - (Pending) [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 1,628,457	$ 1,979,299
Finite-Lived Intangible Assets, Net	$ 1,628,457	$ 1,979,299

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)	Dec. 31, 2020 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 274,669
2022	274,669
2023	274,669
2024	274,669
2025	$ 274,669

INTANGIBLE ASSETS, NET (Details Narrative)	3 Months Ended		12 Months Ended
INTANGIBLE ASSETS, NET (Details Narrative)	Dec. 31, 2020 USD ($) Number	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) Number	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill) \| $	$ 500,000	$ 600,000	$ 1,131,776	$ 78,864
Amortization of Intangible Assets \| $			$ 269,546	$ 197,593	$ 112,474
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			20 years
Domestic US Patents
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	38		38
Foreign Patents Member
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	39		39
Domestic Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	15		15
Foreign Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	9		9
Domestic Patents Non-Approved Bijuva [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	3		3
Domestic US Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	12		12
Domestic US Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	10		10
Domestic US Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	2		2
Foreign Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	18		18
Foreign Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	8		8
Foreign Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	10		10
Domestic Utility Patent Topical Cream Candidates [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1
Domestic Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1
Foreign Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	8		8
Domestic Utility Patent TX009HR
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	3		3
Domestic Patents Progesterone Formulations
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	2		2
Foreign Patents Progesterone Formulations
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	4		4
Domestic Utility Patent Opera
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1

Other current liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued payroll, bonuses and commission costs	$ 8,758,073	$ 8,040,278
Allowance for coupons and returns	6,770,206	10,316,298
Accrued sales and marketing costs	227,500	3,285,662
Accrued compensated absences	2,353,996	1,463,878
Allowance for wholesale distributor fees	2,632,432	2,347,122
Accrued legal and accounting expense	898,568	422,336
Accrued research and development	925,314	1,049,603
Operating lease liability	2,253,994	1,501,539
Accrued rebates	11,010,588	3,916,672
Other accrued expenses	2,339,198	1,480,225
TOTAL OTHER CURRENT LIABILITIES	$ 38,169,869	$ 33,823,613

As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (12,302,469)	$ (5,365,357)
TOTAL LONG-TERM DEBT	237,697,531	194,634,643
Financing Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 250,000,000	$ 200,000,000

The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)	Dec. 31, 2020 USD ($)
Debt Disclosure [Abstract]
2021	$ 50,000,000
2022	25,000,000
2023	133,750,000
2024	41,250,000
2025	$ 0

DEBT (Details Narrative)

3 Months Ended

12 Months Ended

Mar. 01, 2021

USD ($)

Apr. 24, 2019

USD ($)

Number

May 01, 2018

USD ($)

Number

Dec. 31, 2020

USD ($)

Sep. 30, 2020

USD ($)

Jun. 30, 2020

USD ($)

Mar. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

Sep. 30, 2019

USD ($)

^[6]

Jun. 30, 2019

USD ($)

Mar. 31, 2019

USD ($)

Dec. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

Dec. 31, 2018

USD ($)

Nov. 08, 2021

$ / shares

Nov. 08, 2020

USD ($)

$ / shares

Aug. 05, 2020

USD ($)

$ / shares

Repayments of Lines of Credit

$ 22,577,000

^[1]

$ 19,343,000

^{[2],[3],[4],[5]}

$ 10,701,000

$ 12,251,000

$ 15,902,000

$ 23,719,000

$ 6,079,000

^[7]

$ 3,947,000

$ 64,872,280

$ 49,646,937

$ 16,099,460

81,660,719

Minimum cash balance requirement under credit agreement

$ 60,000,000

Number of warrants issued | shares

6,534,687

Shares Issued, Price Per Share | $ / shares

$ 1.1856

Gain (Loss) on Extinguishment of Debt

$ (10,100,000)

(10,057,632)

Amortization of deferred financing costs

2,256,429

856,302

269,859

Write off of deferred financing fees

275,379

Lender Warrants [Member]

Number of warrants issued | shares

4,752,116

Warrants exercise price | $ / shares

$ 1.58

Fair value of warrants

7,400,000

$ 7,428,178

Financing Agreement Amendment No. 6 [Member]

Minimum cash balance requirement under credit agreement

$ 45,000,000

Debt discount

$ 239,983

Financing Agreement Amendment No. 6 [Member] | Lender Warrants [Member]

Warrants exercise price | $ / shares

$ 1.1856

Financing Agreement [Member]

Amortization of deferred financing costs

2,256,428

736,156

Long-term Debt, Gross

$ 250,000,000

200,000,000

250,000,000

200,000,000

Debt Issuance Costs, Gross

$ 7,902,270

7,902,270

Interest Expense, Borrowings

$ 26,049,236

14,709,166

Debt Instrument, Interest Rate, Effective Percentage

12.50%

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2021 [Member]

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2021 [Member]

$ 17,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2021 [Member]

20,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2021 [Member]

23,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2022 [Member]

26,500,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2022 [Member]

30,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2022 [Member]

35,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2022 [Member]

40,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2023 [Member]

45,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2023 [Member]

50,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2023 [Member]

55,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2023 [Member]

60,000,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2024 [Member]

65,500,000

IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]

70,000,000

$ 11,000,000

Tranche Two [Member]

Debt Issuance Costs, Gross

$ 7,626,891

Financing Agreement [Member]

Debt Instrument, Description of Variable Rate Basis

3-month LIBOR

Debt Instrument, Basis Spread on Variable Rate

7.75%

LIBOR floor rate

2.70%

Number of quarterly principal installment payments | Number

Facility fee paid (percent)

2.50%

Minimum cash balance requirement under credit agreement

$ 60,000,000

Financing Agreement [Member] | Prime Rate [Member]

Debt Instrument, Description of Variable Rate Basis

prime rate

Debt Instrument, Basis Spread on Variable Rate

6.75%

Prime rate floor

5.20%

Financing Agreement [Member] | Tranche Two [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 50,000,000

Financing Agreement [Member] | Tranche Three [Member]

Line Of Credit Facility Undrawn Tranche No Longer Available

$ 50,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member]

Repayments of Lines of Credit

$ 15,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayment by March 31, 2021 [Member]

5.00%

5.00%

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on March 31, 2022, June 30, 2022 and September 30, 2022 [Member]

$ 35,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on December 31, 2022 and March 31, 2023 [Member]

5,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024 [Member]

10,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments through March 31, 2022 [Member]

$ 41,250,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayment on March 31, 2022 [Member]

30.00%

5.00%

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments from April 1, 2022 through March 31, 2023 [Member]

$ 5,000,000

Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments from April 1, 2023 through March 31, 2024 [Member]

5.00%

Credit Agreement [Member]

3.00%

Repayment of debt with new credit facility

4.00%

$ 81,661,000

Repayment fee percentage

4.00%

Interest Expense, Debt

1,816,747

4,407,975

Amortization of deferred financing costs

$ 120,146

$ 269,859

Revolving Credit Facility [Member] | Financing Agreement [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 300,000,000

Secured Debt [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 200,000,000

Debt Instrument, Description of Variable Rate Basis

one-month LIBOR

Debt Instrument, Basis Spread on Variable Rate

7.70%

LIBOR floor rate

1.50%

Number of tranches under term loan facility | Number

[1]	During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[2]	During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[3]	During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[4]	During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately $7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. Refer to discussion in Note 8-Debt.
[5]	During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[6]	During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[7]	During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.

Summary of our Warrant activity during the year ended December 31, 2020: (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Number of shares under warrants outstanding beginning \| shares	1,832,571
Weighted average exercise price warrants outstanding beginning \| $ / shares	$ 2.62
Weighted average remaining contractual life, warrants outstanding	1 year 11 months 12 days
Aggregate intrinsic value, warrants outstanding beginning \| $	$ 2,447,929
Number of shares under warrants granted \| shares	4,752,116
Weighted average exercise price warrants granted \| $ / shares	$ 1.19
Cancelled/Forfeited \| shares	(50,000)
Weighted average exercise price warrants cancelled/forfeited \| $ / shares	$ 6.35
Number of shares under warrants outstanding ending \| shares	6,534,687
Weighted average exercise price warrants outstanding ending \| $ / shares	$ 1.55
Weighted average remaining contractual life, warrants outstanding	7 years 3 months
Aggregate intrinsic value, warrants outstanding ending \| $	$ 1,041,219
Number of shares under warrants vested and exercisable ending \| shares	6,534,687
Weighted average exercise price warrants unvested ending \| $ / shares	$ 1.55
Weighted average remaining contractual life, vested and exercisable ending	7 years 3 months
Aggregate intrinsic value, vested and exercisable ending \| $	$ 1,041,219

The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Weighted average exercise price	$ 1.19	$ 5.63	$ 5.16
Weighted average grant date fair value	$ 1.56	$ 3.00	$ 2.79
Risk-free interest rate	0.34%	2.52%	2.36%
Volatility	68.80%	60.80%	62.12%
Term (in years)	10 years	5 years	5 years
Dividend yield	0.00%	0.00%	0.00%

The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price	$ 1.58	$ 3.10	$ 5.45
Weighted average grant date fair value	$ 0.95	$ 1.82	$ 3.24
Risk-free interest rate - minimum	0.34%	1.64%	2.38%
Risk-free interest rate - maximum	1.68%	2.54%	2.89%
Volatility - minimum	63.53%	61.25%	59.45%
Volatility - maximum	67.92%	64.49%	64.04%
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term	6 years	5 years 6 months	5 years 1 month 6 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term	6 years 9 months 18 days	6 years 6 months	6 years 3 months

A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Equity [Abstract]
Number of shares under options, beginning \| shares	25,030,234
Weighted average exercise price, beginning \| $ / shares	$ 4.65
Weighted average remaining contractual life	5 years 10 months 2 days
Aggregate intrinsic value, beginning \| $	$ 3,668,171
Number of shares under options, granted \| shares	736,500
Weighted average exercise price, granted \| $ / shares	$ 1.58
Number of shares under options, exercised \| shares	(1,182,195)
Weighted average exercise price, exercised \| $ / shares	$ 0.23
Aggregate intrinsic value, exercised \| $	$ 1,738,740
Number of shares under options, expired \| shares	(386,609)
Weighted average exercise price, expired \| $ / shares	$ 3.76
Number of shares under options, cancelled forfeited \| shares	(416,000)
Weighted average exercise price, cancelled forfeited \| $ / shares	$ 3.80
Number of shares under options, ending \| shares	23,781,930
Weighted average exercise price, ending \| $ / shares	$ 4.80
Weighted average remaining contractual life	5 years 2 months 12 days
Aggregate intrinsic value, ending \| $	$ 152,253
Number of shares under options, vested and exercisable ending \| shares	19,862,681
Weighted average exercise price, vested and exercisable ending \| $ / shares	$ 5.06
Weighted average remaining contractual life, vested and exercisable	4 years 7 months 2 days
Aggregate intrinsic value, vested and exercisable ending \| $	$ 117,443
Number of shares under options, unvested ending \| shares	3,919,249
Weighted average exercise price, unvested ending \| $ / shares	$ 3.53
Weighted average remaining contractual life, unvested	8 years 3 months 14 days
Aggregate intrinsic value, unvested ending \| $	$ 34,810

Schedule of restricted stock units and performance stock units (Details)

12 Months Ended

Dec. 31, 2020

$ / shares

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Beginning balance, number of shares | shares

1,240,000

Beginning balance, weighted average grant date fair value | $ / shares

$ 3.56

Granted, number of shares | shares

6,152,818

Granted, weighted average grant date fair value | $ / shares

$ 1.39

Vested/Released, number of shares | shares

(301,500)

Vested/Released, weighted average grant date fair value | $ / shares

$ 1.78

Forfeited, number of shares | shares

(30,294)

Forfeited, weighted average grant date fair value | $ / shares

$ 1.07

Ending balance, number of shares | shares

7,061,024

Ending balance, weighted average grant date fair value | $ / shares

$ 1.76

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, number of shares | shares

2,585,745

Granted, weighted average grant date fair value | $ / shares

$ 1.08

Vested/Released, number of shares | shares

(151,500)

Vested/Released, weighted average grant date fair value | $ / shares

$ 1.14

Forfeited, number of shares | shares

(30,294)

Forfeited, weighted average grant date fair value | $ / shares

$ 1.07

Ending balance, number of shares | shares

2,403,951

^[1]

Ending balance, weighted average grant date fair value | $ / shares

$ 1.08

[1]	The number of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the Company’s achievement of break-even quarterly EBITDA.

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)									1 Months Ended		2 Months Ended	11 Months Ended	12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Feb. 16, 2021	Nov. 20, 2020	Nov. 13, 2020	Nov. 10, 2020	Jun. 18, 2020	Oct. 29, 2019	Aug. 06, 2018	Aug. 06, 2018	Feb. 08, 2021	Nov. 30, 2020	Feb. 28, 2021	Nov. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Nov. 08, 2021	Nov. 08, 2020	Aug. 05, 2020
Class of Warrant or Right [Line Items]
Preferred Stock, Shares Authorized													10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share													$ 0.001	$ 0.001
Preferred Stock, Shares Issued													0	0
Preferred Stock, Shares Outstanding													0	0
Common Stock, Shares Authorized													600,000,000	350,000,000
Common Stock, Shares, Issued													299,765,396	271,177,076
Common Stock, Shares, Outstanding													299,765,396	271,177,076
Shares issued for exercise of options, net (in shares)													1,182,195
Shares Issued, Price Per Share																$ 1.1856
Proceeds from Issuance of Common Stock													$ 31,702,635	$ 77,031,258	$ 89,907,797
Number of stock options exercised in cashless exercise (in shares)														12,097	10,000
Number of common stock issued during period for stock options exercised in cashless exercise (in shares)														11,834	9,841
Shares issued in offerings, net of cost													$ 31,702,635	$ 77,031,258	$ 89,907,797
Warrants outstanding													6,534,687
Weighted-average contractual remaining life													7 years 3 months
Non cash compensation expense													$ 10,678,992	$ 10,693,662	8,661,967
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number													23,781,930	25,030,234
Share-based Payment Arrangement, Expense													$ 5,235,585	$ 8,798,707	8,091,294
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount													5,238,000
Restricted Stock or Unit Expense													5,399,472	$ 1,628,407	$ 73,132
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount													$ 9,989,000
2009 Long Term Incentive Compensation Plan [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number													13,285,205
2012 Stock Incentive Plan [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number													6,305,974
Plan 2019 [Member]
Class of Warrant or Right [Line Items]
Award vesting period													4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number													4,190,751
Award expiration period													10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													2,583,565
Employee Stock Purchase Plan [Member]
Class of Warrant or Right [Line Items]
Non cash compensation expense					$ 17,489
Common Stock, Capital Shares Reserved for Future Issuance					5,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					85.00%
Financing Agreement Amendment No. 6 [Member]
Class of Warrant or Right [Line Items]
Debt Discount																	$ 239,983
Warrant [Member]
Class of Warrant or Right [Line Items]
Weighted average exercise price of warrants (in dollars per share)													$ 1.55	$ 2.62
Weighted average grant date fair value, granted													$ 1.56	$ 3.00	$ 2.79
Number of shares under warrants granted													4,752,116
Warrants exercised													0	1,250,000	0
Number of stock issued in cashless exercise of warrants														471,184
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number													6,534,687	1,832,571
Lender Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding																		4,752,116
Class of Warrant or Right, Exercise Price of Warrants or Rights																		$ 1.58
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term													10 years
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate													68.80%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate													0.34%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate													0.00%
Weighted average grant date fair value, granted													$ 1.56
Lender Warrants [Member] \| Financing Agreement Amendment No. 6 [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																	$ 1.1856
Outside Consultants Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares under warrants granted														75,000	175,000
Award vesting period														12 months	12 months
Warrants expiration date														Feb. 13, 2024	Mar. 15, 2023
Warrants [Member]
Class of Warrant or Right [Line Items]
Non cash compensation expense													$ 26,446	$ 254,970	$ 494,136
Maximum [Member]
Class of Warrant or Right [Line Items]
Range - exercise price of options													$ 8.92
Maximum [Member] \| Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights													8.20
Minimum [Member]
Class of Warrant or Right [Line Items]
Range - exercise price of options													0.38
Minimum [Member] \| Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 0.24
Underwriting Agreement Cantor Fitzgerald [Member]
Class of Warrant or Right [Line Items]
Shares issued in offerings, net of cost (in shares)			23,437,500
Shares Issued, Price Per Share				$ 1.1856
Period exercisable underwriters option				30 days
Underwriters option granted in period shares		3,515,625
Proceeds from issuance public offering				$ 31,703,000
Maximum Common Stock Offering Price												$ 50,000,000
Fixed Commission Rate										3.00%
Underwriting Agreement Cantor Fitzgerald [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Shares issued in offerings, net of cost (in shares)	59,459,460								28,600,689
Period exercisable underwriters option	30 days
Underwriters option granted in period shares	8,918,919
Proceeds from Issuance of Common Stock	$ 97,100,000								$ 47,300,000
Underwriting Agreement Cantor Fitzgerald [Member] \| Subsequent Event [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Proceeds from Issuance of Common Stock											$ 50,000,000
Underwriting Agreement JP Morgan Chase [Member]
Class of Warrant or Right [Line Items]
Shares issued in offerings, net of cost (in shares)						26,000,000
Shares Issued, Price Per Share						$ 2.75
Period exercisable underwriters option						30 days
Underwriters option granted in period shares						3,900,000
Proceeds from issuance public offering						$ 77,031,000
Underwriting Agreement Goldman Sachs [Member]
Class of Warrant or Right [Line Items]
Shares issued in offerings, net of cost (in shares)							12,745,098
Shares Issued, Price Per Share							$ 5.10	$ 5.10
Period exercisable underwriters option							30 days
Underwriters option granted in period shares							1,911,764
Proceeds from issuance public offering							$ 69,908,000
Subscription Agreement Knight [Member]
Class of Warrant or Right [Line Items]
Shares issued in offerings, net of cost (in shares)								3,921,568
Shares Issued, Price Per Share							$ 5.10	$ 5.10
Shares issued in offerings, net of cost								$ 20,000,000
Equity Option [Member]
Class of Warrant or Right [Line Items]
Shares issued for exercise of options, net (in shares)													1,182,195	331,619	5,444,526
Shares issued for exercise of options, net													$ 271,678	$ 108,656	$ 1,666,208
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Weighted average grant date fair value, granted													$ 1.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number													7,061,024	1,240,000
Restricted Stock [Member] \| 2012 Stock Incentive Plan [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number													890,000
Restricted Stock [Member] \| Plan 2019 [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number													6,171,024
Performance Stock Units [Member] \| Plan 2019 [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number													2,403,951
Share-based Payment Arrangement, Option [Member]
Class of Warrant or Right [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition													1 year 10 months 24 days
Restricted Stock Units (RSUs) [Member]
Class of Warrant or Right [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition													1 year 7 months 6 days

EMPLOYEE BENEFIT PLAN (Details Narrative) - USD ($)	12 Months Ended
EMPLOYEE BENEFIT PLAN (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Matching contribution percentage	4.00%
Maximum matching contribution per year	$ 2,000
Defined contribution plan vesting service period	5 years
Contributions under plan	$ 487,000	$ 403,000

For financial reporting purposes, (loss) income before taxes includes the following components: (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (183,524,137)	$ (177,144,999)	$ (132,617,160)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (183,524,137)	$ (176,144,999)	$ (132,617,160)

A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%	21.00%	21.00%
State tax rate, net of federal tax benefit	5.10%	4.00%	5.20%
Adjustment in valuation allowances	(27.00%)	(22.50%)	(31.20%)
Excess stock benefits	0.10%	0.20%	5.30%
Federal income tax rate change	0.00%	0.00%	(0.00%)
Permanent and other differences	0.80%	(2.70%)	(0.30%)
Provision (benefit) for income taxes	0.00%	0.00%	0.00%

The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred Income Tax Assets:
Net operating losses	$ 195,008,131	$ 157,555,975	$ 126,419,113
Share based compensation	17,251,900	13,913,568	11,640,464
Interest expense limitation	12,991,716	5,389,129	1,173,614
Other, net	4,818,935	3,662,037	1,658,573
R&D credit	186,347	186,347	186,347
Total deferred income tax asset	230,257,029	180,707,056	141,078,111
Valuation allowance	(230,257,029)	(180,707,056)	(141,078,111)
Deferred income tax assets, net	$ 0	$ 0	$ 0

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Change in valuation allowance	$ 49,549,973	$ 39,628,945	$ 41,295,443
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	761,701,546
Internal Revenue Service (IRS) [Member] \| Expiration Period 20 Years [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	$ 338,775,332
NOL carryforward period	20 years
NOL carryforward expiration year	2031
Internal Revenue Service (IRS) [Member] \| Expiration Period Indefinite [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	$ 422,926,214

RELATED PARTIES (Details Narrative) - USD ($)	12 Months Ended
RELATED PARTIES (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Catalent [Member]
Related Party Transaction [Line Items]
Amount billed	$ 3,036,000	$ 6,101,000	$ 4,111,000
Amounts due to related party	0	$ 35,000
American International Group [Member]
Related Party Transaction [Line Items]
Amount billed	$ 209,000

BUSINESS CONCENTRATIONS (Details Narrative)	12 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Dec. 31, 2020 USD ($) Number	Dec. 31, 2019 USD ($) Number	Dec. 31, 2018 USD ($) Number
Concentration Risk [Line Items]
Number of vendors - suppliers \| Number			3
Supplier One Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	36.00%	24.00%	43.00%
Supplier 2
Concentration Risk [Line Items]
Concentration Risk, Percentage	30.00%	27.00%	33.00%
Supplier 3
Concentration Risk [Line Items]
Concentration Risk, Percentage	25.00%	35.00%	24.00%
Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%	10.00%
Number of customers - revenue \| Number	3	4	4
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	63.00%	73.00%	76.00%
Number of customers - revenue \| Number	3	4	4
Cardinal Health - Major Customer \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Revenues	$ 17,489,000	$ 4,551,000	$ 2,308,000
PillPack - Major Customer \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Revenues	13,228,000	12,676,000	5,075,000
McKesson Corporation - Major Customer \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Revenues	$ 9,862,000	3,911,000	1,610,000
AmerisourceBergen - Major Customer \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Revenues		$ 3,927,000	$ 3,246,000

Supplemental lease information (Details) - USD ($)	12 Months Ended
Supplemental lease information (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Right-of-use asset	$ 9,565,700	$ 10,109,154
Short-term operating lease liability (included in Other current liabilities)	$ 2,253,994	$ 1,501,539
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Long-term operating lease liability	$ 8,675,477	$ 9,145,049
Operating Lease, Weighted Average Remaining Lease Term	8 years 10 months 24 days	9 years
Weighted average discount rate	8.30%	8.25%
Cash paid for amounts included in the measurement of lease liabilities for operating lease	$ 1,617,645	$ 1,164,234
Right-of-use assets obtained in exchange for lease obligation	$ 998,821	$ 11,171,471

The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)	Dec. 31, 2020 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 2,334,582
2022	1,413,289
2023	1,443,143
2024	1,476,534
2025	1,513,458
Thereafter	7,434,412
Total undiscounted lease payments	15,615,418
Less: imputed interest	(4,685,947)
Present value of lease payments	$ 10,929,471

COMMITMENTS AND CONTINGENCIES (Details Narrative)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Aug. 01, 2019 ft²	Jun. 01, 2019 ft²	Oct. 02, 2018 ft²	Jul. 01, 2013
Recorded Unconditional Purchase Obligation [Line Items]
Operating lease term				11 years			63 months
Net rentable area \| ft²						56,212
Rented area lease \| ft²						7,561
Additional rented area occupied under the lease \| ft²				48,651
Number of options to extend lease	2
Lease renewal term	5 years
Lease not yet commenced (area) \| ft²					6,536
Operating Lease, Expense	$ 2,325,844	$ 1,558,794
Variable lease payment	$ 423,578
Rental expense			$ 1,068,275
Significant supply commitment percentage payable	50.00%
Catalent [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Minimum purchase commitment, 2021	$ 3,458,000
Minimum purchase commitment, 2022	2,150,000
Minimum purchase commitment, 2023	2,991,000
Minimum purchase commitment, 2024	3,347,000
Minimum purchase commitment, 2025	3,786,000
ANNOVERA [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Minimum purchase commitment, 2021	$ 1,526,000

Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details) - USD ($)

3 Months Ended

12 Months Ended

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Aug. 05, 2020

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Loss per common share, basic and diluted

$ 22,577,000

^[1]

$ 19,343,000

^{[2],[3],[4],[5]}

$ 10,701,000

$ 12,251,000

$ 15,902,000

$ 23,719,000

^[6]

$ 6,079,000

^[7]

$ 3,947,000

$ 64,872,280

$ 49,646,937

$ 16,099,460

Gross profit

16,996,000

^[1]

16,064,000

^{[2],[3],[4],[5]}

6,301,000

9,536,000

13,023,000

22,275,000

^[6]

4,830,000

^[7]

3,184,000

48,897,303

43,312,352

13,361,808

Net loss

$ (42,088,000)

^[1]

$ (32,611,000)

^{[2],[3],[4],[5]}

$ (51,976,000)

$ (56,849,000)

$ (49,435,000)

$ (31,967,000)

^[6]

$ (55,237,000)

^[7]

$ (39,506,000)

$ (183,524,137)

$ (176,144,999)

$ (132,617,160)

$ (0.15)

^[1]

$ (0.12)

^{[2],[3],[4],[5]}

$ (0.19)

$ (0.21)

$ (0.19)

$ (0.13)

^[6]

$ (0.23)

^[7]

$ (0.16)

$ (0.67)

$ (0.72)

$ (0.59)

Write off of patent and trademark cost

$ 500,000

$ 600,000

$ 1,131,776

$ 78,864

Inventory charge

5,700,000

7,204,818

Loss on extinguishment of debt

$ 10,100,000

$ 10,057,632

Lender Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Fair value of warrants

7,400,000

$ 7,428,178

Knight License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

License Agreement Theramex [Member]

$ 2,000,000

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]